Lurasidone | SM-13496 | 5-HT Receptor Modulator | AmBeed-信号通路专用抑制剂

首页 / / / 多巴胺受体 / Lurasidone

鲁拉西酮 /Lurasidone {[allProObj[0].p_purity_real_show]}

货号：A418721 同义名： SM-13496

Lurasidone functions as an antagonist of the dopamine D2 and D3 receptors, the serotonin 5-HT2A and 5-HT7 receptors, the α2C-adrenergic receptor, and as a partial agonist of the serotonin 5-HT1A receptor.

Lurasidone 化学结构
CAS号：367514-87-2

Lurasidone 3D分子结构
CAS号：367514-87-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Lurasidone 纯度/质量文件产品仅供科研

货号：A418721 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

多巴胺受体亚型比较

产品名称	D1 receptor ↓ ↑	D2 receptor ↓ ↑	D3 receptor ↓ ↑	D4 receptor ↓ ↑	D5 receptor ↓ ↑	DAT ↓ ↑	Dopamine receptor ↓ ↑	其他靶点	纯度
Penfluridol	+ Dopamine receptor, Ki: 1.6 μM								98%
Ansofaxine HCl	++ Dopamine receptor, IC50: 491 nM								98%
Tetrahydroberberine,THB		+ D2 receptor, pKi: 6.08							98+%
Prochlorperazine Maleate		✔							95%
Olanzapine		✔							99+%
Trifluoperazine		++++ Dopamine D2 receptor, IC50: 1.1 nM							98%
Ropinirole hydrochloride		++ D2 receptor, Ki: 29 nM							99%
Lurasidone		++++ D2 receptor, Ki: 1 nM							98%
Levosulpiride		✔							99+%
Pridopidine		✔							95%
Metoclopramide		✔					✔		99+%
Molindone HCl		✔							98%
Sulpiride		✔							99+%
Perospirone		++++ D2 receptor, Ki: 1.4 nM							99%
Perospirone HCl		++++ D2 receptor, Ki: 1.4 nM							98+%
Phenothiazine		✔							98%
Pimozide	+ Dopamine D1 receptor, Ki: 6600 nM	+++ Dopamine D2 receptor, Ki: 3.0 nM	++++ Dopamine D3 receptor, Ki: 0.83 nM						98%
Rotundine	++ D1 receptor, IC50: 166 nM	+ D2 receptor, IC50: 1.47 μM	+ D3 receptor, IC50: 3.25 μM						98%
Domperidone		✔							99+%
ONC206		✔							97%
Pimethixene maleate	++ Dopamine D1 Receptor, pKi: 6.37	+++ Dopamine D2 Receptor, pKi: 8.19		++ Dopamine D4.4 Receptor, pKi: 7.54					97%
Loxapine succinate	++ D1 receptor (human), Ki: 26 nM D2 receptor (Human), Ki: 62 nM	++ D2 receptor (bovine), Ki: 26 nM D2 receptor (human), Ki: 24 nM		+++ D4 receptor (human), Ki: 7.5 nM					99%
Chlorprothixene	+++ D1 receptor, Ki: 18 nM	+++ D2 receptor, Ki: 2.96 nM	+++ D3 receptor, Ki: 4.56 nM		+++ D5 receptor, Ki: 9 nM				98%
SCH-23390 HCl	++++ D1 dopamine receptor, Ki: 0.2 nM				++++ D5 dopamine receptor, Ki: 0.3 nM				98%
MPP+ iodide						✔			97%
σ1 Receptor antagonist-1						+ DAT, pKi: 5.8			97%
Benztropine mesylate						++ DAT, IC50: 118 nM			98%
Azaperone							✔		98%
Ziprasidone HCl							✔		98+%
Paliperidone							✔		98%
Alizapride HCl							✔		99+%
Amisulpride							✔		98%
Quetiapine hemifumarate							✔	Adrenergic Receptor	98%
Clozapine N-oxide							✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Lurasidone 生物活性

靶点

D2 receptor

D2 receptor, IC50:1.68 nM
D2 receptor

D2 receptor, Ki:1 nM

描述

Lurasidone (SM-13496) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM. In vitro receptor binding experiments reveal that Lurasidone (SM-13496) demonstrates affinity for dopamine D2 and 5-HT2A receptors higher than other tested antipsychotics. Lurasidone (SM-13496) dose-dependently increases the ratio of DOPAC/dopamine in frontal cortex and striatum, but it shows a preferential effect on the frontal cortex compare with the striatum, especially at higher doses. Lurasidone (SM-13496) (ED50 values 2.3 to 5.0 mg/kg) shows a comparable potency with olanzapine (ED50 values 1.1 to 5.1 mg/kg), higher potency than clozapine (ED50 9.5 to 290 mg/kg), and slightly lower potency than haloperidol (ED50 values 0.44 to 1.7 mg/kg). Lurasidone (SM-13496) (1 to 10 mg/kg) dose-dependently inhibits conditioned avoidance response (CAR) in rats, and the ED50 values are 6.3 mg/kg. Lurasidone (SM-13496) dose-dependently inhibits tryptamine (TRY)-induced forepaw clonic seizure and p-chloroamphetamine (p-CAMP)-induced hyperthermia with ED50 values of 5.6 and 3.0 mg/kg, respectively. Lurasidone (SM-13496) (0.3 to 30 mg/kg) dose-dependently and significantly increases the number of shocks received by rats in the conflict test with MED of 10 mg/kg^[1]. 80 mg/d lurasidone, an effective and tolerable dose for non-TRS (treatment-resistant schizophrenia) patients, was also effective in TRS patients but required longer duration of treatment^[2]. In the ITT (intention-to-treat) (but not the mITT) population, treatment with lurasidone was associated with significant improvement in the PANSS (Positive and Negative Syndrome Scale) total score in patients with schizophrenia. Lurasidone was generally well tolerated with minimal impact on weight and metabolic parameters^[3].

Lurasidone 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02181803	Schizophrenia	Phase 1	Completed	-	-
NCT01431326	-		Recruiting	February 2020	-
NCT01364818	-		Completed	-	United States, North Carolina ... 展开 >> University of North Carolina Chapel Hill Chapel Hill, North Carolina, United States, 27599 收起 <<

Lurasidone 参考文献

[1]Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334(1):171-81

[2]Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. J Clin Psychopharmacol. 2020 May/Jun;40(3):240-249

[3]Higuchi T, Ishigooka J, Iyo M, Yeh CB, Ebenezer EG, Liang KY, Lee JS, Lee SY, Lin SK, Yoon BH, Nakamura M, Hagi K, Sato T. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. Asia Pac Psychiatry. 2019 Jun;11(2):e12352

Lurasidone 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.03mL

0.41mL

0.20mL

10.15mL

2.03mL

1.01mL

20.30mL

4.06mL

2.03mL

Lurasidone 技术信息

CAS号	367514-87-2
分子式	C₂₈H₃₆N₄O₂S
分子量	492.676

别名	SM-13496
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Room Temperature

溶解度

DMSO: 20 mg/mL(40.59 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

无水乙醇: 3 mg/mL(6.09 mM)，配合低频超声，并水浴加热至45℃助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02181803	Schizophrenia	Phase 1	Completed	-	-
NCT01431326	-		Recruiting	February 2020	-
NCT01364818	-		Completed	-	United States, North Carolina ... 展开 >> University of North Carolina Chapel Hill Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT03565068	Schizophrenia	Phase 1	Suspended(Study is on hold pen... 展开 >>ding evaluation of emerging preclinical findings) 收起 <<	October 9, 2019	United States, California ... 展开 >> California Clinical Trials ( Site 0001) Glendale, California, United States, 91206 收起 <<
NCT02435095	Schizophrenia	Phase 4	Recruiting	April 2019	Germany ... 展开 >> RWTH University Hospital Aachen Recruiting Aachen, NRW, Germany, 52074 Contact: Sabrina Schaffrath saschaffrath@ukaachen.de Contact: Sarah Lammertz slammertz@ukaachen.de Alexianer Aachen GmbH Not yet recruiting Aachen, Germany, 52062 Zentrum für Neurologie und Seelische Gesundheit im Kapuziner Karree Aachen Not yet recruiting Aachen, Germany, 52062 Contact: Frank Bergmann, Dr. med. LVR Klinik Bonn Recruiting Bonn, Germany, 53111 LVR Klinik Düren Not yet recruiting Düren, Germany, 52353 Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf Recruiting Düsseldorf, Germany, 40629 LVR Klinik Essen Not yet recruiting Essen, Germany, 45147 ViaNobis Gangelt Recruiting Gangelt, Germany, 52538 Klinik Königshof (Abteilung für Allgemeine Psychiatrie) Recruiting Krefeld, Germany, 47807 LVR Klinik Langenfeld Recruiting Langenfeld, Germany, 40764 LVR Klinik Viersen Not yet recruiting Viersen, Germany, 41749 收起 <<
NCT02893371	-		Enrolling by invitation	June 2019	United States, New Mexico ... 展开 >> Christophe G Lambert Albuquerque, New Mexico, United States, 87131 收起 <<
NCT03396601	Bipolar Depression ... 展开 >> Suicidal Ideation 收起 <<	Phase 3	Not yet recruiting	March 31, 2020	-
NCT01498770	-		Completed	-	-
NCT03557931	Schizophrenia	Phase 2	Recruiting	December 2019	United States, Arkansas ... 展开 >> Woodland Research Northwest, LLC Recruiting Rogers, Arkansas, United States, 72758 United States, California CNS Research Science, Inc. Recruiting Cerritos, California, United States, 90703 Collaborative Neuroscience Network, LLC Recruiting Garden Grove, California, United States, 92845 Synergy East Recruiting Lemon Grove, California, United States, 91945 Pacific Research Partners, LLC Recruiting Oakland, California, United States, 94607 California Neuropsychopharmacology Clinical Research Institute-LA, LLC Recruiting Pico Rivera, California, United States, 90660 Artemis Institute for Clinical Research Recruiting San Diego, California, United States, 92103 Sharp Mesa Vista Hospital Recruiting San Diego, California, United States, 92123 Collaborative Neuroscience Network, LLC Recruiting Torrance, California, United States, 90502 United States, Georgia Radiant Research, Inc. Recruiting Atlanta, Georgia, United States, 30328 Atlanta Center for Medical Research Recruiting Atlanta, Georgia, United States, 30331 United States, Illinois Alam Medical Research Inc. Recruiting Chicago, Illinois, United States, 60612 Uptown Research Institute Recruiting Chicago, Illinois, United States, 60640 United States, Michigan Michigan Clinical Research Institute PC Recruiting Ann Arbor, Michigan, United States, 48105 Cherry Street Services, Inc. Recruiting Grand Rapids, Michigan, United States, 49503 United States, New Jersey Hassman Research Institute Recruiting Berlin, New Jersey, United States, 08009 United States, New Mexico Albuquerque Neuroscience Inc. Recruiting Albuquerque, New Mexico, United States, 87109 United States, New York SPRI Clinical Trials, LLC Recruiting Brooklyn, New York, United States, 11235 CNS Research Science, Inc. Recruiting Jamaica, New York, United States, 11432 Manhattan Psychiatric Center's 125th Street Clinic Recruiting New York, New York, United States, 10035 United States, Ohio Midwest Clinical Research Center Recruiting Dayton, Ohio, United States, 45417 United States, Texas InSite Clinical Research, LLC Recruiting DeSoto, Texas, United States, 75115 Pillar Clinical Research, LLC Recruiting Garland, Texas, United States, 75042 Pillar Clinical Research, LLC Recruiting Richardson, Texas, United States, 75080 收起 <<
NCT02213887	Psychotic Disorders ... 展开 >> Gastroesophageal Reflux 收起 <<	Phase 4	Active, not recruiting	August 2018	Canada, British Columbia ... 展开 >> UBC Hospital - Detwiller Pavilion Vancouver, British Columbia, Canada, V6T 2A1 收起 <<
NCT01833897	Bipolar Disorder	Phase 4	Completed	-	United States, New York ... 展开 >> New York State Psychiatric Institute New York, New York, United States, 10032 收起 <<
NCT01833897	-		Completed	-	-
NCT00806234	-		Completed	-	-
NCT00806234	Psychotic Disorders	Phase 4	Completed	-	United States, Maryland ... 展开 >> University of Maryland Baltimore, Maryland, United States, 21201 Johns Hopkins Hospital Baltimore, Maryland, United States, 21205 United States, New York The Zucker Hillside Hospital Glen Oaks, New York, United States, 11004 United States, North Carolina University of North Carolina, Division of Child and Adolescent Psychiatry Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT01986101	Bipolar Depression	Phase 3	Completed	-	Japan ... 展开 >> Japan 76 sites Tokyo, Japan Lithuania Lithuania 3 sites Kaunas, Lithuania Malaysia Malaysia 5 sites Kuala Lumpur, Malaysia Philippines Philippines 4 sites Manila, Philippines Russian Federation Russia 19 sites Moscow, Russian Federation Slovakia Slovakia 5 sites Zilina, Slovakia Taiwan Taiwan 7 sites Taipei, Taiwan Ukraine Ukraine 9 sites Kiev, Ukraine 收起 <<
NCT00044044	-		Completed	-	-
NCT02282085	Schizophrenia	Phase 4	Unknown	-	United States, Texas ... 展开 >> UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390 Principal Investigator: Matt Byerly, MD 收起 <<
NCT01614899	Schizophrenia	Phase 3	Completed	-	Japan ... 展开 >> 69 Sites Tokyo, Etc, Japan Korea, Republic of 22 Sites Seoul, Etc, Korea, Republic of Malaysia 10 Sites Kuala Lumpur, Etc, Malaysia Taiwan 14 Sites Taipei, Etc, Taiwan 收起 <<
NCT01614899	-		Completed	-	-
NCT02237417	Schizophrenia	Phase 4	Recruiting	July 2018	United States, Utah ... 展开 >> University of Utah Recruiting Salt Lake City, Utah, United States, 84108 Principal Investigator: Deborah Yurgelun-Todd, PhD 收起 <<
NCT01986114	Bipolar I Disorder	Phase 3	Completed	-	Japan ... 展开 >> Japan 68 sites Tokyo, Japan Lithuania Lithuania 3 sites Kaunas, Lithuania Malaysia Malaysia 5 sites Kuala Lumpur, Malaysia Philippines Philippines 5 sites Manila, Philippines Russian Federation Russia 19 sites Moscow, Russian Federation Slovakia Slovakia 5 sites Zilina, Slovakia Taiwan Taiwan 8 sites Taipei, Taiwan Ukraine Ukraine 9 sites Kiev, Ukraine 收起 <<
NCT01614912	-		Completed	-	-
NCT01173874	Schizophrenia	Phase 3	Completed	-	United States, California ... 展开 >> San Fernando Mental Health Center Granada Hills, California, United States, 91344 University of California - Irvine Orange, California, United States, 92868 United States, Connecticut Yale University New Haven, Connecticut, United States, 06519 United States, Florida University of Miami Department of Psychiatry Miami, Florida, United States, 33136 United States, Georgia Medical College of Georgia Augusta, Georgia, United States, 30912 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 Rush University Psychiatric Clinical Research Center Chicago, Illinois, United States, 60612 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46222 United States, Massachusetts Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55454 United States, Missouri University of Missouri Columbia, Missouri, United States, 65212 United States, New York Columbia University New York, New York, United States, 10032 Psychopharmacology Research Unit- Nathan KIine Institute for Psychiatric Research New York, New York, United States, 10035 United States, North Carolina Duke University Medical Center Butner, North Carolina, United States, 27509 United States, Texas University of Texas Southwestern Medical Center at Dallas Dallas, Texas, United States, 75390 University of Texas Health Science Center, San Antonio San Antonio, Texas, United States, 78229 收起 <<
NCT00044044	Schizophrenia	Phase 2	Completed	-	-
NCT03402152	Bipolar Depression ... 展开 >> Suicidal Ideation 收起 <<	Phase 2 Phase 3	Recruiting	February 28, 2020	United States, New York ... 展开 >> New York State Psychiatric Institute Recruiting New York, New York, United States, 10032 Contact: Joshua T Kantrowitz, MD 646-774-6738 Joshua.Kantrowitz@nyspi.columbia.edu 收起 <<
NCT01614912	Schizophrenia	Phase 3	Completed	-	Japan ... 展开 >> 69 Sites Tokyo, Etc, Japan Korea, Republic of 22 Sites Seoul, Etc, Korea, Republic of Malaysia 10 Sites Kuala Lumpur, Etc, Malaysia Taiwan 14Sites Taipei, Etc, Taiwan 收起 <<
NCT00088634	Schizophrenia	Phase 2	Completed	-	United States, Alabama ... 展开 >> Birmingham Psychiatry Pharmaceutical Birmingham, Alabama, United States, 35209 United States, Arkansas Summit Research Group Little Rock, Arkansas, United States, 72211 United States, California Comprehensive NeuroScience Cerritos, California, United States, 90703 Collaborative Neuro Science Network, Inc. Garden Grove, California, United States, 92845 Optimum Health Services La Mesa, California, United States, 91942 California Clinical Trials San Diego, California, United States, 92123 CNRI, LLC San Diego San Diego, California, United States, 92126 Pacific Clinical Research Upland, California, United States, 91786 United States, District of Columbia Comprehensive NeuroScience, Inc Washington, District of Columbia, United States, 20016 United States, Florida Segal Institute for Clinical Research North Miami, Florida, United States, 33161 The Segal Institute North Miami, Florida, United States, 33161 University of South Florida, Department of Psychiatry and Behavioral Medicine Tampa, Florida, United States, 33613 United States, Georgia Atlanta Center for Medical Research Atlanta, Georgia, United States, 30308 United States, Illinois Comprehensive Neuroscience, Inc. Hoffman Estates, Illinois, United States, 60194 United States, Nevada Robert Lynn Horne, MD, Suite 4 Las Vegas, Nevada, United States, 89102 United States, New Jersey CNS Research Institute Clementon, New Jersey, United States, 08021 United States, Pennsylvania Quantum Clinical Services Group Philadelphia, Pennsylvania, United States, 19139 United States, Texas Community Clinical Research Austin, Texas, United States, 78729 Future Search Trials Austin, Texas, United States, 78756 Claghorn-Lesem Research Clinic Bellaire, Texas, United States, 77401 InSite Clinical Research DeSoto, Texas, United States, 75115 United States, Virginia CBH Health, L.L.C - Dominion Hospital Falls Church, Virginia, United States, 22044 收起 <<
NCT00088634	-		Completed	-	-
NCT01173874	-		Completed	-	-
NCT00711269	Schizophrenia	Phase 3	Completed	-	Japan ... 展开 >> Japan: 67 sites Tokyo, Etc., Japan Korea, Republic of Korea: 14 sites Seoul, Etc., Korea, Republic of Taiwan Taiwan: 11 sites Taipei, Etc., Taiwan 收起 <<
NCT03627195	Schizophrenia	Phase 1	Recruiting	October 15, 2019	United States, California ... 展开 >> Dr. David Walling Recruiting Long Beach, California, United States, 90806 Contact: David Walling, MD 866-787-4257 收起 <<
NCT03395392	Bipolar Depression ... 展开 >> Suicidal Ideation 收起 <<	Phase 2 Phase 3	Not yet recruiting	March 31, 2019	-
NCT00044005	Schizophrenia	Phase 2	Completed	-	United States, Alabama ... 展开 >> Birmingham Psychiatry Pharmaceutical Birmingham, Alabama, United States, 35209 United States, California Institute for Psychopharmacology Research Cerritos, California, United States, 90703 CNS Network Garden Grove, California, United States, 92845 California Clinical Trials Medical Group Glendale, California, United States, 91206 Optimum Health Services La Mesa, California, United States, 91942 University of California, Irvine Orange, California, United States, 92868 California Neuropsychopharmacology Clinical Research Institute San Diego, California, United States, 92126 United States, District of Columbia Psychiatric Institute of Washington Washington, District of Columbia, United States, 20016 United States, Florida Comprehensive Neuroscience. Inc. Melbourne, Florida, United States, 32935 Segal Institute for Clinical Research North Miami, Florida, United States, 33161 University of South Florida Tampa, Florida, United States, 33613 Coordinated Research of Florida, Inc Winter Park, Florida, United States, 32789 United States, Hawaii Hawaii Research Center Honolulu, Hawaii, United States, 96826 United States, Illinois Alexian Brothers Behavioral Health Hospital Hoffman Estates, Illinois, United States, 60194 American Medical Research Oakbrook, Illinois, United States, 60523 United States, Nevada Lake Mead Hospital North Las Vegas, Nevada, United States, 89030 United States, New Jersey Comprehensive Clinical Research, CNS Clementon, New Jersey, United States, 08021 ClinSearch, Inc. Kenilworth, New Jersey, United States, 07033 United States, Pennsylvania Quantum Clinical Services Group Philadelphia, Pennsylvania, United States, 19139 Albert Einstein Medical Center Philadelphia, Pennsylvania, United States, 19141 United States, Texas Community Clinical Research Austin, Texas, United States, 78756 FutureSearch Trials Austin, Texas, United States, 78756 Claghorn Lesem Research Clinic, Inc. Bellaire, Texas, United States, 77401 St. Paul Medical Center Dallas, Texas, United States, 75235 United States, Virginia CNS, Inc. Falls Church, Virginia, United States, 22041 United States, Wisconsin Medstream, Inc. Milwaukee, Wisconsin, United States, 53210 收起 <<
NCT00044005	-		Completed	-	-
NCT01082250	Schizophrenia	Phase 1	Completed	-	United States, California ... 展开 >> California Clinical Trials (CCT) Glendale, California, United States, 91206 收起 <<
NCT00549666	Pharmacokinetics	Phase 1	Completed	-	United States, California ... 展开 >> Covance Global Clinical Pharmacology, Inc. San Diego, California, United States, 92123 收起 <<
NCT00711269	-		Completed	-	-
NCT03396068	Bipolar Depression ... 展开 >> Suicidal Ideation 收起 <<	Phase 2 Phase 3	Not yet recruiting	March 31, 2020	United States, Alabama ... 展开 >> Research Site Active, not recruiting Birmingham, Alabama, United States, 35294 United States, Florida Research Site Active, not recruiting Fort Lauderdale, Florida, United States, 33024 United States, North Carolina Research Site Active, not recruiting Charlotte, North Carolina, United States, 28211 收起 <<
NCT00088621	Schizophrenia	Phase 2	Completed	-	United States, Alabama ... 展开 >> Birmingham Psychiatry Pharmaceutical Birmingham, Alabama, United States, 35209 United States, Arkansas Summit Research Group Little Rock, Arkansas, United States, 72211 United States, California Comprehensive NeuroScience Cerritos, California, United States, 90703 Collaborative Neuro Science Network, Inc. Garden Grove, California, United States, 92845 Optimum Health Services La Mesa, California, United States, 91942 California Clinical Trials San Diego, California, United States, 92123 CA Neutopsychopharmacology Clinical Research Institute (CNRI) San Diego, California, United States, 92126 Pacific Clinical Research Upland, California, United States, 91786 United States, District of Columbia Comprehensive NeuroScience, Inc Washington, District of Columbia, United States, 20016 United States, Florida Segal Institute for Clinical Research Fort Lauderdale, Florida, United States, 33301 Segal Institute for Clinical Research North Miami, Florida, United States, 33161 University of South Florida, Department of Psychiatry and Behavioral Medicine Tampa, Florida, United States, 33613 United States, Illinois Comprehensive Neuroscience, Inc. Hoffman Estates, Illinois, United States, 60194 United States, Nevada Las Vegas, Nevada, United States, 89102 United States, New Jersey CNS Research Institute Clementon, New Jersey, United States, 08021 United States, Pennsylvania Quantum Clinical Services Group Philadelphia, Pennsylvania, United States, 19139 United States, Texas Community Clinical Research Austin, Texas, United States, 78729 Future Search Trials Austin, Texas, United States, 78756 Claghorn Lesem Research Clinic, Inc. Bellaire, Texas, United States, 77401 InSite Clinical Research DeSoto, Texas, United States, 75115 United States, Virginia CBH Health, L.L.C - Dominion Hospital Falls Church, Virginia, United States, 22044 收起 <<
NCT00615433	-		Completed	-	-
NCT01074632	Schizophrenia, Schizoaffective... 展开 >> Disorder, or Schizophreniform Disorder 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> California Clinical Trials Glendale, California, United States, 91206 United States, Kansas Clinical Research Institute Wichita, Kansas, United States, 67207 收起 <<
NCT00790192	Schizophrenia	Phase 3	Completed	-	-
NCT00088621	-		Completed	-	-
NCT00615433	Schizophrenia	Phase 3	Completed	-	-
NCT01082289	Schizophrenia	Phase 1	Completed	-	United States, California ... 展开 >> California Clinical Trials Culver City, California, United States, 90232 收起 <<
NCT01082263	Schizophrenia Patients	Phase 1	Completed	-	United States, California ... 展开 >> CCT/Parexel Culver City, California, United States, 90232 收起 <<
NCT00790192	-		Completed	-	-
NCT00641745	-		Completed	-	-
NCT00641745	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 3	Completed	-	-
NCT00868699	-		Completed	-	-
NCT00549718	Schizophrenia	Phase 3	Completed	-	-
NCT01566162	-		Completed	-	-
NCT00868699	Bipolar Depression	Phase 3	Completed	-	-
NCT01423240	Major Depressive Disorder	Phase 3	Withdrawn	December 2012	-
NCT00549718	-		Completed	-	-
NCT01566162	Schizophrenia	Phase 3	Completed	-	-
NCT00868452	Bipolar Depression	Phase 3	Completed	-	-
NCT01082276	Male, Healthy Normal Subjects	Phase 1	Completed	-	United States, Maryland ... 展开 >> PAREXEL Clinical Pharmacology Research Unit Baltimore, Maryland, United States, 21225 收起 <<
NCT00868452	-		Completed	-	-
NCT01423253	Major Depressive Disorder	Phase 3	Completed	-	United States, Alabama ... 展开 >> Birmingham Psychiatry Pharmaceutical Studies, Inc Birmingham, Alabama, United States, 35226 United States, California Synergy Clinical Research Center Escondido, California, United States, 92025 Collaborative Neuro Science Network, Inc. Garden Grove, California, United States, 92845 Stanford -VA Palo Alto Health Care System Palo Alto, California, United States, 94304 Artemis Institute for Clinical Research San Diego, California, United States, 92123 United States, Florida Florida Clinical Research Center, LLC Sarasota, Florida, United States, 34201 United States, Massachusetts Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders Boston, Massachusetts, United States, 02114 United States, Missouri St. Charles Psychiatric Associates/Midwest Research Group St. Charles, Missouri, United States, 63301 United States, New York Village Clinical Research Inc. New York, New York, United States, 10003 Finger Lakes Clinical Research Rochester, New York, United States, 14618 Behavioral Medical Research of Staten Island Staten Island, New York, United States, 10305 United States, North Carolina Psychiatry and Behavioral Sciences, Duke Durham, North Carolina, United States, 27705 United States, Ohio Midwest Clinical Research Center Dayton, Ohio, United States, 45408 United States, Pennsylvania CRI Worldwide - Kirkbride Philadelphia, Pennsylvania, United States, 19139 United States, Texas FutureSearch Trials of Dallas, LP Dallas, Texas, United States, 75231 Dept. of Psychiatry, UT Southwestern Medical Center Dallas, Texas, United States, 75390-8849 Grayline Clinical Drug Trials Wichita Falls, Texas, United States, 76309 收起 <<
NCT01423253	-		Completed	-	-
NCT02002832	-		Unknown	September 2015	China, Beijing ... 展开 >> Bejing Anding Hospital Recruiting Beijing, Beijing, China, 100088 Contact: pending pending pending caizhuoji@126.com Principal Investigator: Gang Wang 收起 <<
NCT00789698	Chronic Schizophrenia	Phase 3	Completed	-	-
NCT00789698	-		Completed	-	-
NCT02974010	Bipolar Depression ... 展开 >> Suicidal Ideas Suicidal Ideation Suicide, Attempted 收起 <<	Phase 2	Completed	-	United States, Alabama ... 展开 >> Research Site, Birmingham Birmingham, Alabama, United States, 35294 United States, Florida Research Site, Fort Lauderdale Fort Lauderdale, Florida, United States, 33024 United States, North Carolina Research Site, Charlotte Charlotte, North Carolina, United States, 28211 United States, Texas Research Site, Houston Houston, Texas, United States, 77030 收起 <<
NCT01358357	Bipolar I Disorder	Phase 3	Completed	-	-
NCT01358357	-		Completed	-	-
NCT01074073	Schizophrenia	Phase 1	Completed	-	United States, California ... 展开 >> CCT/Parexel Culver City, California, United States, 90232 收起 <<
NCT01421134	-		Completed	-	-
NCT01435928	Schizophrenia	Phase 3	Completed	-	-
NCT01421134	Major Depressive Disorder With... 展开 >> Mixed Features 收起 <<	Phase 3	Completed	-	-
NCT00868959	Bipolar Depression	Phase 3	Completed	-	-
NCT00868959	-		Completed	-	-
NCT01435928	-		Completed	-	-
NCT01932541	Mania Bipolar... 展开 >> I Bipolar II Bipolar Spectrum Disorder Bipolar Disorder 收起 <<	Phase 4	Withdrawn(On hold due to compe... 展开 >>ting departmental studies) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02144 收起 <<
NCT01979679	Schizophrenia	Phase 3	Completed	-	United States, California ... 展开 >> UCI Medical Center Orange, California, United States, 92868 收起 <<
NCT01911429	-		Completed	-	-
NCT01143090	-		Completed	-	-
NCT01569659	Schizophrenia	Phase 4	Completed	-	United States, Illinois ... 展开 >> Northwestern University Department of Psychiatry and Behavioral Sciences Chicago, Illinois, United States, 60611 收起 <<
NCT02174523	Schizophrenia	Phase 1	Completed	-	China, Shanghai ... 展开 >> Xuhui Center Hospital Shanghai, Shanghai, China, 200031 收起 <<
NCT02239094	Bipolar Depression	Not Applicable	Completed	-	United States, New York ... 展开 >> New York State Psychiatric Institute New York, New York, United States, 10032 收起 <<
NCT02239094	-		Completed	-	-
NCT01914393	Schizophrenia ... 展开 >> Autism Bipolar Depression 收起 <<	Phase 3	Completed	-	-
NCT01143090	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 3	Completed	-	-
NCT03465787	Schizophrenia	Phase 3	Recruiting	April 2019	Korea, Republic of ... 展开 >> Borame Medical Center Recruiting Seoul, Seoul, Dongjak-gu, Korea, Republic of, 07061 Contact: Jung Hee Yeon 82-2-870-2461 hyjung@snu.ac.kr Principal Investigator: Jung Hee Yeon, M.D. 收起 <<
NCT01911429	Schizophrenia	Phase 3	Completed	-	-
NCT01143077	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 3	Completed	-	-
NCT01143077	-		Completed	-	-
NCT01485640	Schizophrenia ... 展开 >> Bipolar Disorder 收起 <<	Phase 3	Completed	-	-
NCT01284517	-		Completed	-	-
NCT02046369	Bipolar I Depression	Phase 3	Completed	-	-
NCT02046369	-		Completed	-	-
NCT01082146	Pharmacokinetics ... 展开 >> Metabolism 收起 <<	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Covance Global Clinical Research Unit Inc. Madison, Wisconsin, United States, 53704 收起 <<
NCT01575561	Bipolar I Disorder	Phase 3	Completed	-	-
NCT01485640	-		Completed	-	-
NCT03304457	Schizophrenia	Phase 4	Completed	-	India ... 展开 >> AIIMS Bhubaneshwar, Odisha, India, 751019 收起 <<
NCT02174510	Schizophrenia	Phase 1	Completed	-	China, Shanghai ... 展开 >> Xuhui Center Hospital Shanghai, Shanghai, China, 200031 收起 <<
NCT01575561	-		Completed	-	-
NCT03393026	Schizophrenia	Phase 4	Recruiting	August 2019	Taiwan ... 展开 >> Taipei City Hospital, Songde Branch Recruiting Taipei, Taiwan Contact: Shih-Ku Lin, M.D. (02)2726-3141 Tri-Service General Hospital Recruiting Taipei, Taiwan Contact: Chin-Bin Yeh, M.D., Ph.D. 886-2-87923311 收起 <<
NCT01731119	-		Completed	-	-
NCT01620060	Schizophrenia ... 展开 >> Autism 收起 <<	Phase 1	Completed	-	United States, Arkansas ... 展开 >> Woodland International Research Group, Inc. Little Rock, Arkansas, United States, 72223 Woodland Northwest Research, LLC Springdale, Arkansas, United States, 72704 United States, California World Wide Research Centers Inc. Murrietta, California, United States, 92562 United States, Florida Segal Institute for Clinical Research Ft. Lauderdale, Florida, United States, 33301 Miami Children's Hospital South Miami, Florida, United States, 33143 United States, Georgia Atlanta Center for Medical Research Atlanta, Georgia, United States, 30308 United States, Ohio University of Cincinnati, Dept. of Psychiatry & Behavioral Neuroscience Cincinnati, Ohio, United States, 45219 University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 United States, Pennsylvania CRI Worldwide, LLC Philadelphia, Pennsylvania, United States, 19139 United States, Utah Aspen Clinical Research Orem, Utah, United States, 84058 收起 <<
NCT01284517	Bipolar Depression	Phase 3	Completed	-	-
NCT01911442	-		Completed	-	-
NCT02731612	Bipolar Disorder	Phase 3	Recruiting	December 2019	United States, Massachusetts ... 展开 >> The Brigham and Women's Hospital, Department of Psychiatry Recruiting Boston, Massachusetts, United States, 02115 Contact: Megan Shanahan, MHS 617-732-5790 mshanahan2@bwh.harvard.edu Principal Investigator: Katherine Burdick, Ph.D United States, Ohio University Hospitals Cleveland Medical Center Recruiting Cleveland, Ohio, United States, 44106 Contact: Nicole Moomaw, BA 216-844-2863 Nicole.Moomaw@UHhospitals.org Contact: Carla M Conroy, MPH 216.844.2871 Carla.Conroy@UHhospitals.org Principal Investigator: Joseph R Calabrese, MD Canada, British Columbia UBC Mood Disorders Center Recruiting Vancouver, British Columbia, Canada, V6T 1Z3 Contact: Jayasree Basivireddy, PhD 604-822-3769 jayasree.basivireddy@ubc.ca Contact: Nazlin Walji, BSc. 604-822-7294 nazlin.walji@ubc.ca Principal Investigator: Lakshmi N Yatham Japan Department of Psychiatry, University of Occupational and Environmental Health Not yet recruiting Kitakyushu, Fukuoka, Japan, 807-8555 Contact: Reiji Yoshimura, MD, Ph.D 81-93-603-1611 yoshi621@med.uoeh-u.ac.jp Principal Investigator: Reiji Yoshimura, MD, Ph.D Department of Neuropsychiatry, Kansai Medical University Not yet recruiting Moriguchi-shi, Osaka, Japan, 570-8506 Contact: Masaki Kato, MD, Ph.D 81-6-6992-1001 masaaki-ogasa@ds-pharma.co.jp Principal Investigator: Masaki Kato, MD, Ph.D Department of Psychiatry, Hokkaido University Graduate School of Medicine Not yet recruiting Kita-ku, Sapporo, Japan, 060-8638 Contact: Ichiro Kusumi, MD., Ph.D 81-11-706-5160 Principal Investigator: Ichiro Kusumi, MD, Ph.D National Center of Neurology and Psychiatry Not yet recruiting Kodaira, Tokyo, Japan, 187-8551 Contact: Kazuyuki Nakagome, MD, Ph.D 81-42-341-2711 ext 6200 nakagome@guitar.ocn.ne.jp Principal Investigator: Kazuyuki Nakagome, MD, Ph.D Department of Psychiatry, Fujita Health University School of Medicine Not yet recruiting Aichi, Toyoake, Japan, 470-1192 Contact: Nakao Iwata, MD, Ph.D 81-562-93-2000 Principal Investigator: Nakao Iwata, MD, Ph.D Spain Hospital Clinic de Barcelona, Bipolar Disorder Programme Not yet recruiting Barcelona, Spain, 08036 Contact: Marina Garriga, MD 932275400 ext 3130 MAGARRIGA@clinic.cat Principal Investigator: Eduard Vieta, MD United Kingdom Institute of Psychiatry, Psychology and Neuroscience,King's College London Not yet recruiting London, England, United Kingdom, SE5 8AF Contact: Viktoriya Nikolova, BSc MRes 07795401682 viktoriya.nikolova@kcl.ac.uk Principal Investigator: Allan Young, MB.ChB, Mphil, PhD, 收起 <<
NCT01731119	Schizophrenia ... 展开 >> Schizoaffective Disorder Schizophreniform Disorder Psychosis NOS Autistic Disorder Asperger Syndrome Child Development Disorders, Pervasive Bipolar I Disorder Bipolar II Disorder Mood Disorder NOS Severe Major Depression With Psychotic Features Single Episode Major Depression Without Psychotic Symptoms Severe Mood Disorder With Psychotic Features 收起 <<	Phase 2	Completed	-	United States, North Carolina ... 展开 >> University of North Carolina Chapel Hill, North Carolina, United States, 27517 收起 <<
NCT01620060	-		Completed	-	-
NCT02147379	Bipolar I Disorder	Phase 3	Completed	-	Canada, British Columbia ... 展开 >> University of British Columbia, Department of Psychiatry Vancouver, British Columbia, Canada, V6T 2A1 收起 <<
NCT01911442	Autism	Phase 3	Completed	-	-
NCT01821378	-		Completed	-	-
NCT02199743	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 4	Completed	-	United States, Texas ... 展开 >> UT Southwestern Medical Center Dallas, Texas, United States, 75390 收起 <<
NCT01821378	Schizophrenia	Phase 3	Completed	-	-

鲁拉西酮 /Lurasidone {[allProObj[0].p_purity_real_show]}

Lurasidone 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Lurasidone 质控信息

Lurasidone 生物活性

Lurasidone 临床研究

Lurasidone 参考文献

Lurasidone 实验方案

Lurasidone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

D2 receptor	D2 receptor, IC50:1.68 nM
D2 receptor	D2 receptor, Ki:1 nM

鲁拉西酮 /Lurasidone {[allProObj[0].p_purity_real_show]}

Lurasidone 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Lurasidone 质控信息

Lurasidone 生物活性

Lurasidone 临床研究

Lurasidone 参考文献

Lurasidone 实验方案

Lurasidone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Lurasidone 纯度/质量文件产品仅供科研